循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究

Research on chemosensitivity evaluation using circulating tumor cells in advanced gastrointestinal cancer

目的观察晚期胃肠癌患者中循环肿瘤细胞(CTC)药敏检测与临床化疗疗效的一致性。方法回顾性分析2022年5月至2023年9月在中山大学附属第七医院消化一科住院化疗的31例晚期胃肠癌患者,对比CTC药敏检测结果与临床疗效的一致性。结果总体符合率达64.5%(20/31),阳性结果符合率达59.1%(13/22),阴性结果符合率达77.8%(7/9)。胃癌患者CTC药敏结果与临床疗效一致的符合率为60.0%(6/10),肠癌为66.7%(14/21)。一线、二线、三线及后线治疗临床疗效与CTC药敏结果一致的符合率分别为68.4%(13/19)、71.4%(5/7)、60.0%(3/5)。结论CTC药敏检测对预测晚期胃肠癌患者的化学治疗效果有一定的指导意义,值得临床进一步验证。

Objective To observe the consistency between circulating tumor cells(CTC)drug sensitivity testing and clinical chemotherapy effectiveness in advanced gastrointestinal cancer patients.Methods A retrospective analysis was conducted in 31 advanced gastrointestinal cancer patients who received inpatient chemotherapy in the Department of Gastroenterology,the Seventh Affiliated Hospital of Sun Yat-sen University from May 2022 to September 2023.The results of CTC drug sensitivity testing were compared with clinical outcomes.Results The overall concordance rate was 64.5%(20/31),with a positive result concordance rate of 59.1%(13/22)and a negative result concordance rate of 77.8%(7/9).The consistent coincidence rate was 60.0%(6/10)in gastric cancer and 66.7%(14/21)in bowel cancer.The coincidence rate of clinical efficacy and CTC drug sensitivity was 68.4%(13/19)in first-line treatment,71.4%(5/7)in second-line treatment,and 60.0%(3/5)in third-line and post-line treatment.Conclusion CTC drug sensitivity testing has certain guiding significance in predicting the efficacy of chemotherapy in advanced gastrointestinal cancer patients and deserves further clinical validation.